GO:0019136 deoxynucleoside kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019136 deoxynucleoside kinase activity catalyzes the phosphorylation of 2'-deoxynucleosides to their corresponding 5'-monophosphates using ATP as the phosphate donor.
• This activity is essential for deoxynucleotide salvage, supplying precursors for DNA replication and repair, and its dysfunction leads to mitochondrial DNA depletion syndromes.
• Key enzymes include thymidine kinase 2 (TK2), deoxycytidine kinase (DCK), and deoxyguanosine kinase (DGUOK), which are targeted in antiviral and anticancer therapies.
• Mutations in TK2 cause thymidine kinase 2 deficiency, a mitochondrial myopathy with no approved cure, but deoxynucleoside therapy shows promise.
• Viral kinases such as Epstein-Barr virus thymidine kinase exhibit deoxynucleoside kinase activity and are exploited for prodrug activation.
• Recent studies link deoxynucleoside kinase activity to telomere length regulation through thymidine nucleotide metabolism.
Description
Deoxynucleoside kinase activity (GO:0019136) is a molecular function that enables the phosphorylation of deoxynucleosides to their corresponding 5'-monophosphates, a critical step in the salvage pathway of deoxynucleotide biosynthesis. This activity ensures a balanced supply of dNTPs for DNA replication and repair, and its dysregulation is implicated in mitochondrial diseases and cancer. Understanding this activity is vital for researchers studying nucleotide metabolism, antiviral drug design, and mitochondrial disorders. The enzyme catalyzes the reaction: ATP + 2'-deoxynucleoside = ADP + 2'-deoxynucleoside 5'-phosphate, and it is known by synonyms such as Dm-dNK and multispecific deoxynucleoside kinase. This article explores the mechanism, genes, and research methods associated with GO:0019136, providing a comprehensive resource for biomedical scientists.
deoxynucleoside kinase activity At A Glance
| GO ID | GO:0019136 |
|---|---|
| GO term | deoxynucleoside kinase activity |
| Ontology | molecular_function |
| Synonym | ATP:deoxynucleoside 5'-phosphotransferase activity, Dm-dNK, D. melanogaster deoxynucleoside kinase activity, ms-dNK, Ms-dNK activity, multifunctional deoxynucleoside kinase activity, multispecific deoxynucleoside kinase activity, multisubstrate deoxyribonucleoside kinase activity |
| Major function | Phosphorylation of deoxynucleosides to deoxynucleoside monophosphates |
| Reaction | ATP + 2'-deoxynucleoside = ADP + 2'-deoxynucleoside 5'-phosphate |
| Substrates | Deoxynucleosides (e.g., thymidine, deoxycytidine, deoxyguanosine, deoxyadenosine) |
| Cofactors | Divalent metal ions (e.g., Mg2+) |
| Localization | Cytosol, mitochondria, and nucleus depending on isoform |
What Is GO:0019136?
Deoxynucleoside kinase activity (GO:0019136) is defined as the catalysis of the reaction: ATP + 2'-deoxynucleoside = ADP + 2'-deoxynucleoside 5'-phosphate. In other words, it transfers a phosphate group from ATP to a deoxynucleoside, producing a deoxynucleoside monophosphate and ADP. This activity is a key component of the nucleotide salvage pathway, allowing cells to recycle deoxynucleosides for DNA synthesis.
Why Is deoxynucleoside kinase activity Important in Cell Biology?
Deoxynucleoside kinase activity is crucial for maintaining cellular dNTP pools, which are essential for DNA replication and repair. Defects in this activity cause severe mitochondrial DNA depletion syndromes, such as TK2 deficiency and DGUOK deficiency, leading to myopathies and liver failure. Additionally, viral kinases with this activity are targets for antiviral and anticancer prodrugs, and the activity influences telomere length and genome stability.
• Provides precursors for DNA synthesis via the salvage pathway.
• Mutations cause mitochondrial DNA depletion syndromes (e.g., TK2 deficiency).
• Target for antiviral drugs (e.g., acyclovir activation by viral thymidine kinase).
• Involved in cancer cell proliferation and chemoresistance.
• Regulates telomere length through thymidine nucleotide metabolism.
• Essential for mitochondrial nucleotide homeostasis.
• Potential therapeutic target for deoxynucleoside therapy in mitochondrial diseases.
• Biomarker for mitochondrial myopathies.
• Exploited in gene therapy suicide systems.
• Key enzyme in nucleotide analog activation for imaging and therapy.
Molecular Mechanism of deoxynucleoside kinase activity
Substrate Binding and Specificity
In simple terms: The enzyme grabs a deoxynucleoside and ATP, positioning them for phosphate transfer.
Deoxynucleoside kinases typically exhibit broad substrate specificity, phosphorylating multiple deoxynucleosides such as thymidine, deoxycytidine, and deoxyguanosine. For example, Drosophila melanogaster deoxynucleoside kinase (Dm-dNK) is a multispecific enzyme that phosphorylates all four deoxynucleosides, making it a model for studying substrate recognition. The binding pocket accommodates the deoxyribose moiety and the base, with specificity determined by hydrogen bonding and hydrophobic interactions.
Catalytic Mechanism
In simple terms: ATP donates a phosphate group to the deoxynucleoside, forming a monophosphate product.
The catalytic mechanism involves an in-line transfer of the gamma-phosphate from ATP to the 5'-hydroxyl group of the deoxynucleoside, requiring divalent metal ions like Mg2+ for neutralization and stabilization. This results in the formation of ADP and deoxynucleoside 5'-monophosphate. The reaction is reversible under certain conditions but favors phosphorylation in vivo.
Cofactors and Metal Ion Requirement
In simple terms: Magnesium ions help the enzyme work by stabilizing the ATP phosphate groups.
Deoxynucleoside kinases require divalent metal ions, typically Mg2+, for activity. These ions coordinate with the phosphate groups of ATP, facilitating nucleophilic attack by the deoxynucleoside hydroxyl group. The absence of Mg2+ drastically reduces catalytic efficiency, as shown in kinetic studies of TK2 and DGUOK.
Regulation and Compartmentalization
In simple terms: The enzyme's location and activity are controlled to meet cellular needs.
Deoxynucleoside kinases are regulated at multiple levels, including transcriptional control, post-translational modifications, and subcellular localization. For instance, TK2 is localized to mitochondria, where it phosphorylates thymidine for mitochondrial DNA synthesis, while DCK is cytosolic and nuclear. Compartmentalization ensures balanced dNTP pools in different organelles, and dysregulation can lead to nucleotide imbalances and disease.
Key Genes Involved in GO:0019136 deoxynucleoside kinase activity
The following genes encode enzymes with deoxynucleoside kinase activity or are directly involved in the salvage pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TK2 | Phosphorylates thymidine and deoxycytidine in mitochondria | Mutations cause TK2 deficiency, a mitochondrial DNA depletion myopathy |
| DGUOK | Phosphorylates deoxyguanosine and deoxyadenosine in mitochondria | Defects lead to mitochondrial DNA depletion syndrome with liver failure |
| DCK | Phosphorylates deoxycytidine, deoxyguanosine, and deoxyadenosine in cytosol/nucleus | Target for anticancer and antiviral nucleoside analogs |
| TK1 | Phosphorylates thymidine in cytosol during S phase | Marker of cell proliferation and cancer |
| CMPK2 | Phosphorylates deoxycytidine monophosphate to diphosphate | Interacts with TK2 in mitochondrial nucleotide metabolism |
| NT5C | Dephosphorylates deoxynucleoside monophosphates | Regulates dNTP pools and opposes kinase activity |
| Dm-dNK | Multispecific deoxynucleoside kinase from Drosophila | Model enzyme for studying broad substrate specificity |
| EBV-TK | Thymidine kinase from Epstein-Barr virus | Viral kinase with deoxynucleoside kinase activity, target for prodrugs |
| GUK1 | Guanylate kinase 1, phosphorylates GMP to GDP | Deficiency causes mitochondrial DNA depletion |
| RRM1 | Ribonucleotide reductase subunit, converts NDPs to dNDPs | Indirectly supports dNTP synthesis |
| RRM2 | Ribonucleotide reductase subunit | Regulates dNTP pools for DNA replication |
| TYMS | Thymidylate synthase, de novo thymidylate synthesis | Balances with salvage pathway |
| SAMHD1 | dNTP triphosphohydrolase, regulates dNTP pools | Mutations cause Aicardi-Goutières syndrome |
| NME1 | Nucleoside diphosphate kinase, produces dNTPs | Supports nucleotide metabolism |
| NME2 | Nucleoside diphosphate kinase | Regulates dNTP pools |
| AK1 | Adenylate kinase 1 | Maintains nucleotide balance |
| AK2 | Adenylate kinase 2 | Mitochondrial nucleotide homeostasis |
How Is deoxynucleoside kinase activity Regulated?
Deoxynucleoside kinase activity is regulated by substrate availability, feedback inhibition by dNTPs, and post-translational modifications. For example, TK2 activity is inhibited by high concentrations of dTTP, ensuring balanced thymidine nucleotide pools. Additionally, the expression of DCK is cell-cycle dependent, peaking during S phase to support DNA replication. Compartmentalization further regulates activity, with mitochondrial and cytosolic isoforms responding to distinct nucleotide demands.
deoxynucleoside kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TK2 | TK2 deficiency myopathy | TK2 knockout mouse, patient-derived myotubes |
| DGUOK | Mitochondrial DNA depletion syndrome 3 | DGUOK knockout hepatocytes, zebrafish |
| DCK | Chemoresistance in leukemia | DCK knockout cancer cell lines |
| EBV-TK | EBV-associated lymphomas | EBV-infected B cell lines |
| CMPK2 | Mitochondrial nucleotide imbalance | CMPK2 knockout cells |
Mitochondrial DNA Depletion Syndromes
Mutations in TK2 and DGUOK, which encode deoxynucleoside kinases, cause mitochondrial DNA depletion syndromes characterized by severe myopathy, liver failure, and neurological symptoms. TK2 deficiency leads to loss of mitochondrial DNA in muscle, resulting in progressive weakness, and deoxynucleoside therapy has shown preclinical efficacy. DGUOK mutations primarily affect the liver and brain, highlighting the tissue-specific consequences of impaired deoxynucleoside kinase activity.
Cancer and Chemoresistance
Deoxynucleoside kinases are critical for activating nucleoside analog drugs used in cancer therapy, such as cytarabine and gemcitabine. Altered expression or mutations in DCK can lead to chemoresistance, as cancer cells fail to phosphorylate and activate these prodrugs. Additionally, increased deoxynucleoside kinase activity supports the high proliferation rate of cancer cells by maintaining dNTP pools.
Viral Infections and Antiviral Targets
Viruses such as Epstein-Barr virus and herpes simplex virus encode their own deoxynucleoside kinases, which phosphorylate antiviral prodrugs like acyclovir, leading to chain termination and viral DNA synthesis inhibition. These viral kinases exhibit unique substrate specificities distinct from human enzymes, making them selective targets for antiviral therapy.
From deoxynucleoside kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TK2 cause mitochondrial DNA depletion? | TK2 knockout cell line (CRISPR) |
| Can a point mutation in DGUOK alter substrate specificity? | DGUOK point-mutation knock-in cells |
| Does overexpression of DCK sensitize cancer cells to cytarabine? | DCK overexpression cell line |
| How does tagging TK2 affect its mitochondrial localization? | TK2 tagged knock-in (e.g., GFP) |
| What is the effect of EBV-TK on prodrug activation? | EBV-TK overexpression in B cells |
| Can CRISPR screening identify synthetic lethal partners of TK2? | Genome-wide CRISPR library screening |
How to Study the deoxynucleoside kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric kinase assay | Enzymatic activity with radiolabeled substrates | Kinetic characterization of TK2, DGUOK |
| LC-MS/MS | dNTP and deoxynucleoside levels | Quantifying pool imbalances in disease models |
| CRISPR knockout | Loss-of-function phenotypes | Studying gene essentiality and drug resistance |
| CRISPR knock-in | Point mutation effects | Modeling patient mutations in TK2 |
| RNA-seq | Transcriptional changes | Identifying compensatory pathways |
| Proteomics | Protein expression and interactions | Mapping signaling networks |
| Immunofluorescence | Subcellular localization | Determining mitochondrial vs cytosolic isoforms |
| CRISPR library screening | Genome-wide fitness and synthetic lethality | Identifying targets for combination therapy |
Enzymatic Assays
Deoxynucleoside kinase activity is typically measured using radiometric assays with 3H-labeled deoxynucleosides, followed by separation of phosphorylated products by thin-layer chromatography or HPLC. These assays allow determination of kinetic parameters such as Km and Vmax for different substrates.
CRISPR-Cas9 Knockout and Knock-in
CRISPR-Cas9 is used to generate knockout cell lines for genes encoding deoxynucleoside kinases, enabling studies of their roles in dNTP pool maintenance and drug sensitivity. Knock-in of point mutations can model patient-specific variants, such as those in TK2 or DGUOK, to assess functional consequences.
Metabolomics and dNTP Pool Analysis
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is employed to quantify dNTP pools in cells with altered deoxynucleoside kinase activity, revealing imbalances that contribute to disease. This method is sensitive and can detect femtomole levels of nucleotides.
RNA-seq and Proteomics
Transcriptomic and proteomic analyses can identify changes in gene expression and protein interactions following modulation of deoxynucleoside kinase activity, providing insights into regulatory networks and compensatory pathways.
How CRISPR Can Be Used to Study GO:0019136 deoxynucleoside kinase activity
Knockout
CRISPR knockout of deoxynucleoside kinase genes such as TK2 or DGUOK in cell lines results in depleted dNTP pools and mitochondrial DNA depletion, mimicking patient phenotypes. These models are used to test rescue strategies, including deoxynucleoside supplementation.
Point Mutation
Knock-in of patient-specific point mutations (e.g., TK2 H90N) using CRISPR allows precise modeling of enzyme dysfunction and assessment of residual activity. Such models help correlate genotype with biochemical and cellular phenotypes.
Knock-in
Tagged knock-in of deoxynucleoside kinases (e.g., GFP or FLAG) enables live-cell imaging and proteomic analysis of localization and interactions. This approach is valuable for studying mitochondrial targeting sequences.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of deoxynucleoside kinases like DCK can sensitize cancer cells to nucleoside analogs, providing a tool for drug discovery. Overexpression models also help study the effects of elevated dNTP pools on genome stability.
How EDITGENE Supports deoxynucleoside kinase activity Research
Researchers studying deoxynucleoside kinase activity-related genes often need to determine whether a candidate gene is causally involved in mitochondrial disease, cancer, or antiviral responses. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for deoxynucleoside kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DGUOK Knockout HEK293 Cell Line | EDJ-KQ2089 | Human | 1716 | Details Get a Quote |
| DCK Knockout HEK293 Cell Line | EDJ-KQ4426 | Human | 1633 | Details Get a Quote |
| TK2 Knockout HEK293 Cell Line | EDJ-KQ17908 | Human | 7084 | Details Get a Quote |
| DGUOK Knockout HCT 116 Cell Line | EDJ-KQ22182 | Human | 1716 | Details Get a Quote |
| DGUOK Knockout HeLa Cell Line | EDJ-KQ22183 | Human | 1716 | Details Get a Quote |
| DCK Knockout A-549 Cell Line | EDJ-KQ26962 | Human | 1633 | Details Get a Quote |
| DCK Knockout HCT 116 Cell Line | EDJ-KQ26963 | Human | 1633 | Details Get a Quote |
| DCK Knockout HeLa Cell Line | EDJ-KQ26964 | Human | 1633 | Details Get a Quote |
| DGUOK Knockout A-549 Cell Line | EDJ-KQ20888 | Human | 1716 | Details Get a Quote |
| TK2 Knockout A-549 Cell Line | EDJ-KQ25698 | Human | 7084 | Details Get a Quote |
| TK2 Knockout HCT 116 Cell Line | EDJ-KQ25699 | Human | 7084 | Details Get a Quote |
| TK2 Knockout HeLa Cell Line | EDJ-KQ25700 | Human | 7084 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About deoxynucleoside kinase activity
What is deoxynucleoside kinase activity?
Deoxynucleoside kinase activity (GO:0019136) is the catalysis of the reaction: ATP + 2'-deoxynucleoside = ADP + 2'-deoxynucleoside 5'-phosphate, a key step in nucleotide salvage.
What genes are involved in deoxynucleoside kinase activity?
Key genes include TK2, DGUOK, DCK, TK1, and viral kinases such as EBV-TK, each with distinct substrate specificities and cellular roles.
What diseases are associated with deoxynucleoside kinase activity?
Mutations in TK2 and DGUOK cause mitochondrial DNA depletion syndromes, while altered DCK activity is linked to cancer chemoresistance.
How is deoxynucleoside kinase activity measured?
It is measured using radiometric assays with labeled deoxynucleosides, often coupled with HPLC or LC-MS/MS for product detection.
What is the role of TK2 in mitochondrial DNA maintenance?
TK2 phosphorylates thymidine and deoxycytidine in mitochondria, providing dNTPs for mitochondrial DNA replication; its deficiency leads to mtDNA depletion.
Can deoxynucleoside kinase activity be targeted for cancer therapy?
Yes, nucleoside analogs like cytarabine require activation by deoxynucleoside kinases such as DCK, and modulating this activity can overcome chemoresistance.
What is the difference between TK1 and TK2?
TK1 is cytosolic and cell-cycle regulated, while TK2 is mitochondrial and constitutively expressed, each serving distinct dNTP pool needs.
How does Epstein-Barr virus thymidine kinase differ from human kinases?
EBV-TK has unique substrate specificity and can phosphorylate antiviral prodrugs like acyclovir, making it a selective antiviral target.
What model systems are used to study deoxynucleoside kinase activity?
Common models include CRISPR knockout cell lines, patient-derived fibroblasts, and mouse models, often complemented by enzymatic and metabolomic assays.
What is the clinical significance of deoxynucleoside kinase activity in mitochondrial myopathies?
Deficiencies in TK2 or DGUOK cause severe mitochondrial myopathies, and deoxynucleoside therapy is being explored as a treatment.
Conclusion
Deoxynucleoside kinase activity (GO:0019136) is a fundamental molecular function in nucleotide metabolism, with critical roles in DNA replication, mitochondrial homeostasis, and drug activation. Its dysfunction underlies severe mitochondrial diseases and influences cancer therapy outcomes. Continued research using advanced CRISPR models and metabolomic tools will further elucidate its regulatory mechanisms and therapeutic potential.
References
- 1. Mannherz W et al.. 2023. Thymidine nucleotide metabolism controls human telomere length.. Nat Genet 55(4):568-580 PMID: 36959362
- 2. de Barcelos IP et al.. 2019. Advances in primary mitochondrial myopathies.. Curr Opin Neurol 32(5):715-721 PMID: 31408013
- 3. Hidalgo-Gutierrez A et al.. 2024. Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease.. Ann Neurol 96(6):1209-1224 PMID: 39230499
- 4. Ward AS et al.. 2025. Compartmentalized thymidine phosphorylation by mitochondrial nucleotide kinases TK2 and CMPK2.. J Biol Chem 301(11):110733 PMID: 40967432
- 5. Koronkiewicz M et al.. 2022. Antitumor activity of the protein kinase inhibitor 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.. BMC Cancer 22(1):1069 PMID: 36243702
- 6. Lopez-Gomez C et al.. 2021. Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency.. Ann Neurol 90(4):640-652 PMID: 34338329
- 7. Stinchcombe T et al.. 1985. Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines.. Biochemistry 24(8):2027-33 PMID: 2990549
- 8. Mannherz W et al.. 2025. Metabolic constraint of human telomere length by nucleotide salvage efficiency.. Nat Commun 16(1):3000 PMID: 40148339
